Next Article in Journal
Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma
Next Article in Special Issue
Sphingosine 1-Phosphate Receptor 2 Induces Otoprotective Responses to Cisplatin Treatment
Previous Article in Journal
Protein Oxidative Damage in UV-Related Skin Cancer and Dysplastic Lesions Contributes to Neoplastic Promotion and Progression
Previous Article in Special Issue
The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma
Open AccessReview

Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma

Centre for Cancer Biology, University of South Australia and SA Pathology, UniSA CRI Building, North Tce, Adelaide, SA 5001, Australia
Department of Neurosurgery, Flinders Medical Centre, Adelaide, SA 5042, Australia
Adelaide Medical School and School of Biological Sciences, University of Adelaide, SA 5001, Australia
Author to whom correspondence should be addressed.
Cancers 2020, 12(1), 111;
Received: 5 December 2019 / Revised: 28 December 2019 / Accepted: 30 December 2019 / Published: 1 January 2020
(This article belongs to the Special Issue The Sphingolipid Pathway in Cancer)
Glioblastoma (GBM) is the most commonly diagnosed malignant brain tumor in adults. The prognosis for patients with GBM remains poor and largely unchanged over the last 30 years, due to the limitations of existing therapies. Thus, new therapeutic approaches are desperately required. Sphingolipids are highly enriched in the brain, forming the structural components of cell membranes, and are major lipid constituents of the myelin sheaths of nerve axons, as well as playing critical roles in cell signaling. Indeed, a number of sphingolipids elicit a variety of cellular responses involved in the development and progression of GBM. Here, we discuss the role of sphingolipids in the pathobiology of GBM, and how targeting sphingolipid metabolism has emerged as a promising approach for the treatment of GBM. View Full-Text
Keywords: glioblastoma; sphingolipid; ceramide; sphingosine 1-phosphate glioblastoma; sphingolipid; ceramide; sphingosine 1-phosphate
Show Figures

Figure 1

MDPI and ACS Style

Tea, M.N.; Poonnoose, S.I.; Pitson, S.M. Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma. Cancers 2020, 12, 111.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop